Sun Pharma Advanced Research Company Ltd Financials
Company Logo

Sun Pharma Advanced Research Company Ltd Financial Statement

Sun Pharma Advanced Research Company Ltd Income Statement

Quarterly

Annual

*All values are in Rs. Cr

Particulars
Mar 2025
Revenue27.19
Operating Expense81.11
Net Profit-60.98
Net Profit Margin-224.27
Earning Per Share-1.88
EBIDTA-53.92
Effective Tax RateTBA

Sun Pharma Advanced Research Company Ltd Profit & Loss

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2025
Total Revenue Annual71.77
Operating Expenses Annual399.04
Operating Profit Annual-325.49
Interest Annual8.91
Depreciation10.83
Net Profit Annual-345.22
Tax AnnualTBA

Sun Pharma Advanced Research Company Ltd Cash Flow

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2025
Cash Flow at the Beginning5.06
Cash Flow from Operations-362.41
Cash Flow from Investing157.66
Cash Flow from Financing200.88
Cash Flow at the End1.19

Sun Pharma Advanced Research Company Ltd Key Ratios

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2025
PBDIT Margin (%)-453.50
PBIT Margin (%)-468.59
PBT Margin (%)-415.99
Net PROFIT Margin (%)-481.01
Return On Networth / Equity (%)TBA
Return On Networth /Employed (%)TBA
Return On Assets (%)-168.35
Total Debt / Equity (X)TBA
Asset Turnover Ratio (%)0.35

Sun Pharma Advanced Research Company Ltd Balance Sheet

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2025
Fixed Assets Annual148.92
Total Current Assets Annual25.26
Non Current Assets Annual304.02
Total Shareholders Funds Annual-220.62
Total Assets Annual329.28

Sun Pharma Advanced Research Company Ltd Earning Calls

EPS (INR)

Expected

0.00

Reported

-1.84

Surprise

0.00%

Dec 2024

EPS beaten by 0.00%

Sep 2024

EPS beaten by 0.00%

Jun 2024

EPS beaten by 0.00%

FAQS on Sun Pharma Advanced Research Company Ltd Financials

As of Jul 27, 2025, Sun Pharma Advanced Research Company Ltd has a market capitalization of 4,802.92 Cr. Value Research classifies it as a Mid-Cap company.

Yes, Sun Pharma Advanced Research Company Ltd is with a debt-to-equity ratio of -1.20.

In FY 2024 , Sun Pharma Advanced Research Company Ltd recorded a total revenue of approximately 71.77 Cr marking a significant milestone in the company's financial performance.

Sun Pharma Advanced Research Company Ltd's Future outlook anticipates robust growth, with forecasted earnings and revenue rising approximately -0.1% and -0.6% annually, respectively..

Sun Pharma Advanced Research Company Ltd's current PE ratio is -13.91.

Sun Pharma Advanced Research Company Ltd's ROCE averaged -159.7% from the FY ending March 2023 to 2025, with a median of -135.4%. It peaked at -33.3% in March 2023, reflecting strong capital efficiency over the period..

Sun Pharma Advanced Research Company Ltd's latest EBIT is Rs. -336.31 Cr, surpassing the average EBIT of Rs. -312.57 Cr over the 5 years..

Join the Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions